Surgery after neoadjuvant immunotherapy in patients with resectable non-small cell lung cancer.

ABSTRACT: Surgery is the standard of care for patients with operable non-small cell lung cancer (NSCLC). However, as a single modality, surgery for early stage or locally advanced NSCLC remains associated with high rates of local and distant recurrence. The addition of neoadjuvant or adjuvant chemotherapy has modestly improved outcomes. While systemic therapy paired with surgery for other malignancies such as breast cancer have resulted in far better outcomes for equivalent stage designations, outcome improvements for operable NSCLC have lagged in part as a result of trials where adjuvant chemotherapy seemed to incur harm for stage IA patients and only modest survival benefit for stage IB-IIIA patients (AJCC 7^th ed.). In recent years, immunotherapy for NSCLC has emerged as a systemic ther

SUBMITTER: Huynh C 

PROVIDER: S-EPMC7867741 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature